Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucentis versus Ozurdex for macular edema following central retinal vein occlusion
2011-001020-38Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2011
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of ranibizumab, ozurdex in central retinal vein occlusion (CRVO), macular edema, sponsored by Novartis. Started Apr 2011; status: completed.
02
Drugs
ranibizumabozurdex
03
Conditions
central retinal vein occlusion (CRVO)macular edema
Beyond the preview
Go deeper on 2011-001020-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001020-38.